These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 3454501

  • 41. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE, Anania C, Malinak R.
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [Abstract] [Full Text] [Related]

  • 42. Treatment of hirsutism with combined pill containing drospirenone.
    Gregoriou O, Papadias K, Konidaris S, Bakalianou K, Salakos N, Vrachnis N, Creatsas G.
    Gynecol Endocrinol; 2008 Apr; 24(4):220-3. PubMed ID: 18382909
    [Abstract] [Full Text] [Related]

  • 43. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
    Greco T, Graham CA, Bancroft J, Tanner A, Doll HA.
    Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
    [Abstract] [Full Text] [Related]

  • 44. Effects of a cyproterone-containing oral contraceptive on hormonal levels in polycystic ovarian disease.
    Calaf-Alsina J, Rodriguez-Espinosa J, Cabero-Roura A, Lenti-Paoli O, Mora-Brugues J, Esteban-Altirriba J.
    Obstet Gynecol; 1987 Feb; 69(2):255-8. PubMed ID: 2949170
    [Abstract] [Full Text] [Related]

  • 45. Androgen excess in cystic acne.
    Marynick SP, Chakmakjian ZH, McCaffree DL, Herndon JH.
    N Engl J Med; 1983 Apr 28; 308(17):981-6. PubMed ID: 6220224
    [Abstract] [Full Text] [Related]

  • 46. Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary.
    Vrbikova J, Dvorakova K, Hill M, Starka L.
    Endocr Regul; 2006 Dec 28; 40(4):119-23. PubMed ID: 17201585
    [Abstract] [Full Text] [Related]

  • 47. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A, De Leo V.
    Minerva Ginecol; 2007 Aug 28; 59(4):415-25. PubMed ID: 17923832
    [Abstract] [Full Text] [Related]

  • 48. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul 28; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 49. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
    Sänger N, Stahlberg S, Manthey T, Mittmann K, Mellinger U, Lange E, Kuhl H, Wiegratz I.
    Contraception; 2008 Jun 28; 77(6):420-5. PubMed ID: 18477491
    [Abstract] [Full Text] [Related]

  • 50. Sex hormone binding globulin: effect of synthetic steroids on the assay and effect of oral contraceptives.
    Bowles SM, Mills RJ.
    Ann Clin Biochem; 1981 Jul 28; 18(Pt 4):226-31. PubMed ID: 7197136
    [Abstract] [Full Text] [Related]

  • 51. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
    Maier PS, Mattiello SS, Lages L, Spritzer PM.
    Gynecol Endocrinol; 2012 Aug 28; 28(8):606-10. PubMed ID: 22329763
    [Abstract] [Full Text] [Related]

  • 52. Effects of ethinyl estradiol and desogestrel on clinical and metabolic parameters in Indian patients with polycystic ovary syndrome.
    Bhattacharya SM, Ghosh M, Basu R.
    J Obstet Gynaecol Res; 2012 Jan 28; 38(1):285-90. PubMed ID: 22070369
    [Abstract] [Full Text] [Related]

  • 53. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome.
    Raj SG, Raj MH, Talbert LM, Sloan CS, Hicks B.
    Obstet Gynecol; 1982 Jul 28; 60(1):15-9. PubMed ID: 7201126
    [Abstract] [Full Text] [Related]

  • 54. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
    Suikkari AM, Tiitinen A, Stenman UH, Seppälä M, Laatikainen T.
    Fertil Steril; 1991 May 28; 55(5):895-9. PubMed ID: 1708731
    [Abstract] [Full Text] [Related]

  • 55. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
    Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG.
    J Clin Endocrinol Metab; 1991 Jan 28; 72(1):83-9. PubMed ID: 1898744
    [Abstract] [Full Text] [Related]

  • 56. The effect of an oral contraceptive containing ethinylestradiol and desogestrel on hair growth and hormonal parameters of hirsute women.
    Ruutiainen K.
    Int J Gynaecol Obstet; 1986 Oct 28; 24(5):361-8. PubMed ID: 2880770
    [Abstract] [Full Text] [Related]

  • 57. Effect of contraceptive steroids on serum levels of sex hormone binding globulin and caeruloplasmin.
    Limpongsanurak S, Jenkins N, Fotherby K.
    Curr Med Res Opin; 1981 Oct 28; 7(3):185-91. PubMed ID: 7194172
    [Abstract] [Full Text] [Related]

  • 58. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
    Mastorakos G, Koliopoulos C, Creatsas G.
    Fertil Steril; 2002 May 28; 77(5):919-27. PubMed ID: 12009344
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Contraception and therapy with Tri Regol tablet.
    Adám J.
    Ther Hung; 1991 May 28; 39(2):75-7. PubMed ID: 1948781
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.